~~<i id='07DFD78C9B'><strike id='07DFD78C9B'><tt id='07DFD78C9B'><pre id='07DFD78C9B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

leisure time

author：leisure time 2025-09-27 12:55:54 - browse：26659

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Hubble vs. James Webb telescope images: See the difference

focus

hotspot

entertainment

knowledge

entertainment

ForensicmedicalexaminersworkatthescenewhereanunidentifiedmanwaskilledinApatzingan,Mexico,Sunday,July

WSS

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Kenai launches with $82 million for Parkinson’s stem cell therapy

AstraZeneca lung cancer study comes in below expectations

AstraZeneca loses challenge to Medicare drug price negotiation

Kenai launches with $82 million for Parkinson’s stem cell therapy

Drug cartel violence flares in western Mexico after vigilante leader's killing

Wikipedia

leisure time

focus

Affirmative action in medical school literally saved lives

Canadians with cystic fibrosis outlive Americans by a decade

The cancer drug shortage isn’t new — and neither are the solutions

International team creates first chimeric human

Trump demands the U.S. pay no more for drugs than other countries … again

Pfizer highlights cancer drugs it thinks could reignite investor interest

Wildfire smoke exposes gaps in outdoor worker protections

AstraZeneca loses challenge to Medicare drug price negotiation

Bright Health sells Medicare Advantage business to Molina

A letter from the executive editor: The 2023 STATUS List

hotspot

'Screen and refer' systems are hurting patients

Fatty liver disease was alleviated by Lilly’s ‘triple

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

How to address the problem of discarded donor organs

What affirmative action's end means to a medical student

entertainment

knowledge

knowledge

entertainment